Internal Medicine, Medical Oncology · Gainesville, FL
NPI
1417031238
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
6420 W Newberry Rd, East Wing, Suite 100
Gainesville, FL, 32605
Phone (352) 332-3900
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.3M
371,198 services
Medicare patients, 2024
1,366
Average age 76
Drug cost, 2024
$3.0M
1,528 prescriptions
Company payments, 2025
$1,096
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Laura C Dickerson was code Q0138 (injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)), 120,870 times for 120 patients. In total Laura C Dickerson billed 371,198 services in 154 codes, and Medicare paid $4.3M.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-05-02.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 120,870 | 120 | $0.27 | $33K |
| J9264 Injection, paclitaxel protein-bound particles, 1 mg | Office | 19,200 | 14 | $10.75 | $206K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 14,340 | 40 | $6.35 | $91K |
| J0897 Injection, denosumab, 1 mg | Office | 14,220 | 102 | $20.47 | $291K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 14,000 | 24 | $44.55 | $624K |
| J0185 Injection, aprepitant, 1 mg | Office | 10,270 | 22 | $1.33 | $14K |
| J1756 Injection, iron sucrose, 1 mg | Office | 6,700 | 16 | $0.16 | $1,053 |
| J9267 Injection, paclitaxel, 1 mg | Office | 5,444 | 12 | $0.08 | $449 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 5,244 | 162 | $0.09 | $466 |
| 85025 Blood Count | Office | 3,067 | 1,185 | $7.60 | $23K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,790 | 52 | $0.74 | $2,056 |
| 36415 Venipuncture Blood Collection | Office | 2,742 | 1,168 | $8.64 | $24K |
| J9395 Injection, fulvestrant, 25 mg | Office | 1,950 | 18 | $6.15 | $12K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 1,500 | 14 | $15.89 | $24K |
| 99214 Office E&M - Established | Office | 1,225 | 655 | $92.81 | $114K |
By year: 2022 $3.5M for 256,578 services; 2023 $3.7M for 289,719 services; 2024 $4.3M for 371,198 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 3,067 | 1,185 | $7.60 | $23K |
| 36415 Venipuncture Blood Collection | 2,742 | 1,168 | $8.64 | $24K |
| 85045 Blood Count | 92 | 87 | $3.91 | $360 |
| 81003 Clinical Chemistry | 72 | 19 | $2.20 | $158 |
Medicare prescription drug claims, 2024
In 2024, the drug Laura C Dickerson prescribed most often to Medicare patients was Anastrozole, with 307 prescriptions and refills. In total Laura C Dickerson wrote 1,528 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 307 | 885 | 113 | $6,190 |
| Eliquis Apixaban | 101 | 166 | 24 | $96K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 67 | 67 | 23 | $1,581 |
| Oxycodone Hcl Generic | 66 | 66 | 23 | $1,060 |
| Gabapentin Generic | 64 | 92 | 16 | $661 |
| Tamoxifen Citrate Generic | 52 | 156 | 18 | $1,230 |
| Ondansetron Odt Ondansetron | 51 | 57 | 39 | $1,470 |
| Revlimid Lenalidomide | 46 | 46 | Under 11 | $852K |
| Morphine Sulfate Er Morphine Sulfate | 44 | 44 | 11 | $1,480 |
| Prochlorperazine Maleate Generic | 43 | 45 | 35 | $621 |
| Levofloxacin Generic | 38 | 38 | 35 | $119 |
| Dexamethasone Generic | 38 | 48 | 15 | $1,018 |
| Hydroxyurea Generic | 38 | 109 | 16 | $1,540 |
| Xarelto Rivaroxaban | 37 | 51 | Under 11 | $28K |
| Letrozole Generic | 32 | 96 | 13 | $690 |
Brand drugs: 334 claims; generic drugs: 1,194 claims; opioid claims: 217.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Laura C Dickerson $1,096 ($1,096 in general payments such as food, travel and fees) from 20 companies. The largest payer was Genzyme Corporation with $176.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 6 | $176 |
| Boston Scientific Corporation BSX | 1 | $152 |
| AstraZeneca Pharmaceuticals LP AZN | 4 | $92.49 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $81.51 |
| EMD Serono, Inc. MRK.DE | 3 | $67.27 |
| Astellas Pharma US Inc 4503.T | 3 | $65.22 |
| Daiichi Sankyo Inc. 4568.T | 2 | $56.35 |
| Taiho Oncology, Inc. 4578.T | 2 | $51.7 |
| Abbvie Inc. ABBV | 3 | $51.25 |
| Pfizer Inc. PFE | 2 | $45.77 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.